

**To:** [redacted] [redacted]@rivm.nl; [redacted] [redacted]@rivm.nl  
**From:** [redacted]  
**Sent:** Tue 2/9/2021 5:43:48 PM  
**Subject:** RE: For your review: Risk of death for healthcare workers from COVID-19 manuscript  
**Received:** Tue 2/9/2021 5:43:49 PM

Nu lopen er 2 dingen door elkaar: artikel dat we bespreken morgen is van nivel. Gaat over impact influenza vaccinatie op huisarts consulten en een vervolg studie. [redacted] is daarbij co auteur omdat er virologische data in staan tav circulerende stammen en match vaccin.

Bij dit artikel hebben [redacted] en ik commentaar gegeven, aansluitend bij dat van [redacted] dat er veel bias is en we het niet eens zijn met de conclusie en een volgende versie tegemoet zien.

Als die er is, laat ik het weten. We hebben ook (nog) geen namen van co auteurs doorgegeven.

Groet [redacted]

---

**Van:** [redacted] <[redacted]@rivm.nl>  
**Datum:** 9 februari 2021 om 18:14:00 CET  
**Aan:** [redacted] <[redacted]@rivm.nl>, [redacted] <[redacted]@rivm.nl>  
**Onderwerp:** RE: For your review: Risk of death for healthcare workers from COVID-19 manuscript

[redacted]

Groeten,  
[redacted]

---

**From:** [redacted] <[redacted]@rivm.nl>  
**Sent:** Friday, January 29, 2021 5:14 PM  
**To:** [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>  
**Subject:** RE: For your review: Risk of death for healthcare workers from COVID-19 manuscript

Dank [redacted]

[redacted]

---

**From:** [redacted] <[redacted]@rivm.nl>  
**Sent:** woensdag 27 januari 2021 23:52  
**To:** [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>  
**Subject:** RE: For your review: Risk of death for healthcare workers from COVID-19 manuscript

Dank je [redacted] heb 'm snel gereviewed, zie attachment.  
[redacted]

---

**From:** [redacted] <[redacted]@rivm.nl>  
**Sent:** woensdag 27 januari 2021 16:41  
**To:** [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>  
**Subject:** FW: For your review: Risk of death for healthcare workers from COVID-19 manuscript

Hebben jullie dit ook ontvangen? Ik moet het zelf nog lezen, maar deel het vast.

Groet

5.1.2e

**From:** ECDC respiratory viruses <5.1.2e@ecdc.europa.eu>  
**Sent:** woensdag 27 januari 2021 15:04  
**To:** 5.1.2e@meduniwien.ac.at; 5.1.2e@ages.at; 5.1.2e@thl.fi; 5.1.2e@hpsc.ie;  
 5.1.2e@hse.ie; 5.1.2e@hse.ie; 5.1.2e@ins.etat.lu; 5.1.2e@rivm.nl;  
 5.1.2e@uvzsr.sk; 5.1.2e@gov.mt; 5.1.2e@rivm.nl;  
 5.1.2e@rivm.nl; 5.1.2e@rivm.nl; 5.1.2e@gov.mt;  
 5.1.2e@gov.mt; 5.1.2e@uvzsr.sk; 5.1.2e@fhi.no; 5.1.2e@rivm.nl;  
 5.1.2e@rivm.nl; 5.1.2e@rivm.nl; 5.1.2e@meduniwien.ac.at;  
 5.1.2e@ages.at; 5.1.2e@thl.fi; 5.1.2e@thl.fi; 5.1.2e@hpsc.ie; 5.1.2e@hse.ie;  
 5.1.2e@hse.ie; 5.1.2e@iss.it; 5.1.2e@iss.it; 5.1.2e@opbg.net; 5.1.2e@ms.etat.lu;  
 5.1.2e@gov.mt; 5.1.2e@gov.mt; 5.1.2e@rivm.nl;  
 5.1.2e@rivm.nl; 5.1.2e@fhi.no; 5.1.2e@fhi.no; 5.1.2e@uvzsr.sk; 5.1.2e@uvzsr.sk;  
 5.1.2e@folkhalsomyndigheten.se; 5.1.2e@folkhalsomyndigheten.se  
**Cc:** 5.1.2e@ecdc.europa.eu; ECDC respiratory viruses <5.1.2e@ecdc.europa.eu>; 5.1.2e@who.int  
 <5.1.2e@who.int>

**Subject:** For your review: Risk of death for healthcare workers from COVID-19 manuscript

Dear Operational Contact Points for COVID-19 (Epidemiology),  
 Dear National Focal Points for Viral Respiratory Diseases,

Dear colleagues,

ECDC has prepared a draft manuscript for submission to *the Journal of Emerging Infectious Diseases* published by CDC titled, *Risk of death for healthcare workers when hospitalized with COVID-19 from January 2020 to January 2021 in 10 EU/EEA countries*.

In this special study, ECDC analysed case-based surveillance data comparing risk factors for mortality in hospitalised healthcare worker cases and hospitalised non-healthcare workers.

Please review the draft manuscript in track changes and provide comments where necessary. The references have not yet been formatted and remain in the comments for your consideration.

Please reply with the names, emails, and affiliations of those who should be included in the list of co-authors and/or acknowledgements.

All co-authors will be contacted to provide their final agreement to the paper prior to submission.

Please send all of your tracked changes and comments to 5.1.2e@ecdc.europa.eu and copy 5.1.2e@ecdc.europa.eu by **COB Wednesday, 03 February 2021**.

With thanks and best wishes,

5.1.2e on behalf of the ECDC and WHO Europe COVID-19 Teams



**European Centre for Disease Prevention and Control (ECDC)**

Gustav III:s boulevard 40, 169 73 Solna, Sweden

5.1.2e

[www.ecdc.europa.eu](http://www.ecdc.europa.eu)

Follow ECDC on:



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.